Sharper & Granite’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
PR
Sharper & Granite's XBI Position: Q3 2026 in Review
Sharper & Granite increased its State Street SPDR S&P Biotech ETF (XBI) stake by 8.3% in Q3 2026, buying an estimated $82.6K and bringing the position to 6,789 shares worth $867K. The position accounts for 0.3% of the portfolio, ranked #68.
Sharper & Granite first reported a position in XBI in Q4 2022 and has held it in 16 quarters since. The position peaked at $1.15M in Q3 2024. 521 funds tracked by Wall St. Rank hold XBI as of Q3 2026.
- Sharper & Granite held 6,789 shares of State Street SPDR S&P Biotech ETF worth $867K as of Q3 2026.
- Sharper & Granite bought 523 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $82.6K.
- State Street SPDR S&P Biotech ETF made up 0.3% of Sharper & Granite's portfolio in Q3 2026, its #68 holding.
- Sharper & Granite first reported a position in State Street SPDR S&P Biotech ETF in Q4 2022 and has held it in 16 quarters since.
- Sharper & Granite's State Street SPDR S&P Biotech ETF position peaked at $1.15M in Q3 2024.
- 521 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.
Based on Sharper & Granite's 13F filing for Q3 2026, filed 2 Nov 2026.